BRIEF REPORT: Impact of age and SARS-CoV-2 breakthrough infection on humoral immune

responses after three doses of COVID-19 mRNA vaccine

Francis Mwimanzi[1], Hope R. Lapointe[2], Peter K. Cheung[1,2], Yurou Sang[1], Fatima Yaseen[1], Rebecca
Kalikawe[1], Sneha Datwani[1], Laura Burns[3], Landon Young[3], Victor Leung[4,5], Siobhan Ennis[1], Chanson
J. Brumme[2,4], Julio S.G. Montaner[2,4], Natalie Prystajecky[5,6], Christopher F. Lowe[3,5], Mari L.
DeMarco[3,5], Daniel T. Holmes[3,5], Janet Simons[3,5], Masahiro Niikura[1], Marc G. Romney[3,5,*], Zabrina L.
Brumme[1,2,*], Mark A. Brockman[1,2,*]
9
1. Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6, Canada;
2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, V6Z 1Y6, Canada;
3. Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, V6Z 1Y6, Canada;
4. Department of Medicine, University of British Columbia, Vancouver, V6T 1Z3, Canada;
5. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,
V6T 1Z7, Canada
6. British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, V5Z 4R4,
Canada
18
*MAB, MGR and ZLB contributed equally

Corresponding Author Contact Information:

Mark A. Brockman, Ph.D.

Professor, Faculty of Health Sciences, Simon Fraser University

8888 University Drive, Burnaby, BC, Canada, V5A 1S6

Tel: 778 782-3341; Fax: 778-782-5927;

email: mark_brockman@sfu.ca

ABSTRACT

Longitudinal immune response data following three-dose COVID-19 mRNA vaccination remain

limited, particularly in older adults and those experiencing their first SARS-CoV-2 infection. We

quantified wild-type- and Omicron-specific antibody concentrations and virus neutralization activity up

to six months post-third-dose in COVID-19-naive adults aged 24-98 years. Among participants who

remained COVID-19-naïve, antibody concentrations were comparable between age groups over time.

Omicron-specific neutralization declined more rapidly in older adults, and at six months was

undetectable in 56% and 96% of COVID-19-naive younger and older adults, respectively. Post-vaccine

SARS-CoV-2 breakthrough infections increased wild-type- and Omicron-specific responses above

three-dose vaccination alone, illustrating beneficial hybrid immunity.

Key words: COVID-19, mRNA vaccine, humoral immunity, hybrid immunity, post-vaccination

infection, older adults, binding antibodies, viral neutralization, Omicron

INTRODUCTION

Third COVID-19 mRNA vaccine doses, provided to immunocompromised and clinically-vulnerable individuals to complete their initial vaccine series [1-3] or as "booster" doses in the general population to offset natural antibody decline and augment responses against the more immune-evasive Omicron variants [4], enhanced protection against severe disease [1, 5, 6] but did not prevent widespread Omicron-driven infections [7, 8]. Few studies have assessed post-third-dose immune response durability across the adult age spectrum, nor compared vaccine-induced to "hybrid" antibody responses elicited by three-dose vaccination followed by SARS-CoV-2 breakthrough infection, information that could help inform the design and delivery of future vaccine boosters.

In a prior study, we reported that older adults mounted weaker antibody responses than younger adults after two vaccine doses, but equivalent initial responses after three doses [9]. Here, we longitudinally examine wild-type- and Omicron-specific antibody concentration and function up to six months post-third-dose in 116 individuals who remained COVID-19-naïve until at least one month post-third-dose. One-third of participants experienced SARS-CoV-2 (presumably Omicron) infection during follow-up, allowing us to additionally compare vaccine-induced and "hybrid" immune responses [10].

METHODS

Participants. Our British Columbia (BC), Canada, cohort has been described previously [9]. Here, we studied the subset of 69 healthcare workers (HCW) and 47 older adults (OA) who remained COVID-19 naive until at least one month after their third COVID-19 mRNA vaccine dose (**Table S1**). Post-vaccine SARS-CoV-2 infections were detected by the development of serum antibodies against

Nucleocapsid (N) using the Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics), combined with

diagnostic (PCR- and/or rapid-antigen-test-based) information.

Ethics approval. Written informed consent was obtained from all participants or their authorized

decision makers. This study was approved by the University of British Columbia/Providence Health

Care and Simon Fraser University Research Ethics Boards.

Assays. We quantified IgG-binding antibodies in serum against the SARS-CoV-2 Spike Receptor

Binding Domain (RBD) using the V-plex SARS-CoV-2 (IgG) ELISA kit (Panel 22; Meso Scale

Diagnostics), which features WT (Wuhan) and Omicron (BA.1) RBD antigens, on a Meso QuickPlex

SQ120 instrument. Serum was diluted 1:10000, with results reported in Arbitrary Units (U)/mL. We

assessed surrogate virus neutralization activity [11] in serum by competition ELISA using the same kit

(Panel 22; V-plex SARS-CoV-2 [ACE2]) to measure blockade of the RBD-ACE2 receptor interaction.

Sera were diluted 1:40 and results reported as % ACE2 displacement. A subset of specimens was also

tested for IgG-binding antibodies and ACE2 displacement using V-plex assays that featured Wuhan,

BA.1, BA.2 and BA.3 Spike antigens (Panel 25). Virus neutralizing activity in plasma was examined

using live WT (USA-WA1/2020; BEI Resources) and Omicron BA.1 (GISAID EPI_ISL_9805779)

viruses on VeroE6-TMPRSS2 (JCRB-1819) target cells [9]. Virus stocks were diluted to 50

$TCID_{50}$/200 µl in the presence of serial 2-fold plasma dilutions (1/20 to 1/2560) and added to target

cells in triplicate. Viral cytopathic effects (CPE) were recorded three days post-infection.

Neutralization was reported as the highest reciprocal dilution able to prevent CPE in all three wells.

Partial or no neutralization at 1/20 dilution was considered below the limit of quantification (BLOQ).

RESULTS

Participant characteristics

HCW and OA were a median of 40 and 78 years old, respectively (range 24-98 years old), and predominantly female (**Table S1**). OA were predominantly of white ethnicity (74%, compared to 46% of HCW) and had more chronic health conditions (median of 1, interquartile range [IQR] 0-2 in OA versus 0 [IQR 0-1] in HCW). Most participants (97% of HCW and 81% of OA) initially received two BNT162b2 doses. Third doses were predominantly mRNA-1273 (52% of HCW and 62% of OA), which were administered in an age-dependent manner per local guidelines: most OA received 100 mcg whereas HCW received 50 mcg. Third doses were administered an average of ~7 months after the second. During follow-up, 43% of HCW and 17% of OA experienced their first SARS-CoV-2 infection; based on local epidemiology most were suspected to be Omicron BA.1 or BA.2 [12].

Binding antibodies

As reported previously [9, 13], anti-RBD serum IgG concentrations were lower in COVID-19-naive OA compared to younger HCW after two vaccine doses, but the third dose significantly enhanced these responses (**Figure 1A**). One month post-third dose, WT-specific anti-RBD IgG concentrations were equivalent in the two groups: a median of 5.21 (IQR 5.08-5.45) $\log_{10}$ U/mL in HCW versus 5.25 (IQR 4.99-5.43) in OA (p=0.7). Among COVID-19-naive participants, WT-specific IgG responses declined to a median 4.95 (IQR 4.79-5.16) in HCW versus 4.96 (IQR 4.76-5.17) in OA at three months post-third dose (p=0.9), and to a median 4.64 (IQR 4.42-4.84) in HCW versus 4.59 (IQR 4.35-4.87) in OA by six months (p=0.7). By six months, IgG concentrations in COVID-19-naive HCW had declined to below post-second-dose levels (p<0.0001) while in OA they had declined to comparable levels as achieved by two doses (p=0.2). Following three doses, the half-life of WT-specific IgG was estimated

to be a median 73 (IQR 53-101) days in COVID-19-naive HCW versus 69 (IQR 54-91) days in OA (p=0.8; **Figures 1B, 1C**).

By contrast, individuals who experienced SARS-CoV-2 infection during follow-up exhibited markedly higher IgG concentrations than their COVID-19-naive counterparts at three and six months post-third dose (both p<0.0001; **Figure 1A**). Notably, at six months, IgG concentrations in "hybrid immunity" participants were a median 5.50 (IQR 5.17-5.79) $\log_{10}$ U/mL, which was significantly higher than their responses induced by three vaccine doses alone (p=0.0005). Individual-level longitudinal responses are detailed in **Figure S1.** Identical trends were observed for Omicron (BA.1)-specific IgG concentrations, though these were on average ~0.6 $\log_{10}$ lower than WT-specific responses at all time points (**Figure 1A**; **Figure S1**). In COVID-19-naive individuals, Omicron-specific IgG half-lives were similar to WT-specific ones and were comparable between OA (median 75 days [IQR 58-93]) and HCW (78 [IQR 64-94]) (p=0.5; **Figure S2**).

ACE2 displacement

While ACE2 displacement activities against WT and Omicron (BA.1) variants were lower in COVID-19-naive OA compared to HCW following two vaccine doses, these responses increased to equivalence one month post-third dose: a median 98.7% (IQR 96.3-99.3) in HCW versus 99.3% (IQR 96.0-99.7) OA for WT (p=0.12), and a median of 62.5% (IQR 46.2-75.5) in HCW versus 66.2% (IQR 44.6-79.3) in OA for Omicron BA.1 (p=0.4) (**Figure 2A**). Among COVID-19-naive participants, WT-specific ACE2 displacement activities declined similarly in both groups, to a median 98.0% (IQR 93.7-99.3) in HCW versus 98.3% (IQR 91.7-99.5) in OA at three months post-third dose (p=0.9), and a median 92.8% (IQR 80.0-99.9) in HCW versus 91.4% (IQR 72.3-97.1) in OA at six months (p=0.4). Omicron-specific ACE2 displacement declined slightly faster in OA, particularly between 3-6 months,

to a median 48.6% (IQR 20.5-73.8) in HCW versus 47.6% (IQR 14.2-71.7) in OA at three months

post-third dose (p=0.4), and a median 43.3% (IQR 13.4-62.2) in HCW versus 20.7% (IQR 5.6-32.3) in

OA at six months (p=0.04). By six months post-third dose, WT- and Omicron-specific ACE2

displacement activities in COVID-19-naive HCW had declined to below post-second-dose levels

(p<0.0001 and p=0.02 respectively), while in COVID-19-naive OA they had declined to comparable

levels as achieved after two doses (p=0.6 and p=0.4, respectively). By contrast, post-vaccination

SARS-CoV-2 infection induced a strong functional boost: at six months, ACE2 displacement activities

against both WT and Omicron in the hybrid immunity group significantly exceeded those originally

induced by three vaccine doses alone (both comparisons p<0.0001; **Figure 2A**; also see **Figure S1**).

Omicron-specific ACE2 displacement activities for example rose to a median 95.9% (IQR 90.0-97.8)

in the hybrid group at six months.

Virus neutralization

Live virus neutralization activity was weaker in OA versus younger HCW following two

vaccine doses, but it reached equivalence one month post-third-dose when reciprocal plasma dilutions

required to neutralize WT were a median 320 (IQR 160-320) in HCW versus a median 320 (IQR 80-

640) in OA (p=0.9), while those required to neutralize Omicron (BA.1) were a median 40 (IQR 20-80)

in both groups (p=0.8) (**Figure 2B**). Among COVID-19-naive participants, WT neutralization declined

relatively similarly in both groups, to median reciprocal dilutions of 80 (IQR 80-160) in HCW versus

80 (IQR 40-160) in OA at three months post-third dose (p=0.03), and a median 40 (IQR 20-80) in

HCW versus 20 (IQR 20-80) in OA at six months (p=0.3). By contrast, Omicron-specific neutralization

declined faster in OA, to median reciprocal dilutions of 40 (IQR 20-80) in HCW versus BLOQ (IQR

BLOQ-BLOQ) in OA at three months (p=0.004), and BLOQ (IQR BLOQ-20) in HCW versus BLOQ

[IQR BLOQ-BLOQ] in HCW at six months (p=0.003). At six months, neutralization function in

COVID-19-naive participants had declined to below post-second-dose levels (*e.g.* WT-specific p-

values <0.05; **Figure 2B**), and Omicron-specific-neutralization was BLOQ in 56% and 96% of

COVID-19-naive HCW and OA, respectively. By contrast, post-vaccination SARS-CoV-2 infection

induced a strong neutralization boost: at six months, WT- and Omicron-specific neutralization

activities in the hybrid group significantly exceeded those induced by three vaccine doses alone (all

p≤0.002; **Figure 2B;** also see **Figure S2**). Omicron-specific neutralization for example was a median

reciprocal dilution of 80 (IQR 80-160) in the hybrid group at six months (**Figure 2B**).

Responses to other Omicron variants

To estimate immune responses to other Omicron variants, we quantified anti-Spike IgG levels

and ACE2 displacement activities specific to WT, BA.1, BA.2 and BA.3 variants in 25 participants one

month post-third-dose. Compared to WT-specific responses, anti-Spike IgG concentrations were on

average ~0.4 $\log_{10}$ lower for Omicron variants, while ACE2 displacement activities were on average at

least 30% lower for Omicron variants (all p<0.0001; **Figure S3**). BA.2-specific anti-Spike IgG

concentrations were comparable to BA.1 (p=0.2), while BA.2-specific ACE2 displacement activities

were marginally lower (p=0.01). BA.3-specific anti-Spike IgG concentrations and ACE2 displacement

activities were significantly lower than BA.1 (both p<0.0001), though the magnitude of these

differences was modest (*e.g.* median IgG was 5.42 $\log_{10}$ for BA.1 versus 5.35 $\log_{10}$ for BA.3). The

correlation between anti-Spike and anti-RBD measurements for the WT and BA.1 antigens was strong

(Spearman's ρ≥0.86, p<0.0001; **Figure S3**).

DISCUSSION

A third COVID-19 mRNA vaccine dose significantly enhances antibody responses in SARS-

CoV-2-naive individuals, including to the Omicron variant, and particularly in older adults. At one,

three and six months post-third-dose, WT- and Omicron-specific anti-RBD binding IgG concentrations

were of comparable magnitude and declined at similar rates in older and younger adults, though

Omicron-specific responses were consistently ~0.6 $\log_{10}$ lower than WT. Longitudinal WT-specific

ACE2 displacement and neutralization activities were also similar between groups, but older adults

displayed lower Omicron-specific ACE2 displacement activity at six months post-third dose, and lower

Omicron-specific neutralization at both three and six months post-third dose compared to younger

adults. This is consistent with impaired Omicron-specific antibody function in older adults that is only

revealed as antibody concentrations decline. Notably, by six months post-third-dose, antibody

responses in COVID-19-naive participants of all ages had declined markedly to or below those initially

elicited by two-dose vaccination, with anti-Omicron neutralization below the limit of quantification in

56% of younger and 96% of older adults by this time (79% of OA were already BLOQ at 3 months).

By contrast, both younger and older adults who experienced their first SARS-CoV-2 infection

(presumably Omicron BA.1 or BA.2 [12]) after three-dose vaccination demonstrated superior binding

and functional humoral responses to those induced by triple-vaccination alone. This is consistent with

other studies of hybrid immunity [10, 14, 15] and suggests that a post-third-dose infection may provide

prolonged immune protection. The observation that immune enhancement was most pronounced for

Omicron-specific responses (*e.g.* see Figure 2A), and extended to antibody function, is likely

attributable to exposure to Omicron Spike. If so, heterologous booster vaccination with variant Spike

antigens may offer similar benefits.

Though these findings further underscore the immune benefits of third/booster doses in all ages,

they suggest that COVID-19-naive individuals, particularly older adults, may benefit from an

additional booster dose by six months. By contrast, individuals who contracted their first SARS-CoV-2

infection following three-dose vaccination may benefit less from a booster within this time frame.

Exposure to Omicron-like antigens, whether from infection or a multivalent vaccine that includes

variant Spike/RBDs, will likely elicit superior immune responses against circulating variants compared

to immunization with existing, WT-only vaccines. Additional studies are needed to assess the

durability of hybrid immune responses and to evaluate cross-reactivity against emerging viral variants.

ACKNOWLEDGEMENTS

We thank the leadership and staff of Providence Health Care, including long-term care and

assisted living residences, for their support of this study. We thank the phlebotomists and laboratory

staff at St. Paul's Hospital, the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research

and Innovation Centre, and Simon Fraser University for assistance. Above all, we thank the

participants, without whom this study would not have been possible.

FUNDING

This work was supported by the Public Health Agency of Canada through a COVID-19

Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB, MAB).

Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 and

the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB), the Canada Foundation

for Innovation through Exceptional Opportunities Fund – COVID-19 awards (to MAB, MD, MN,

ZLB). FM is supported by a fellowship from the CIHR Canadian HIV Trials Network. FY was

supported by an SFU Undergraduate Research Award. MLD and ZLB hold Scholar Awards from the

Michael Smith Foundation for Health Research.

FIGURE LEGENDS

Figure 1. Serum anti-RBD IgG concentrations following three-dose COVID-19 vaccination. *Panel*

A: Longitudinal serum anti-RBD IgG concentrations specific to WT (left side) and Omicron BA.1

(right side) in COVID-19-naive health care workers (HCW; blue circles) and older adults (OA; orange

circles). Any participant who experienced a SARS-CoV-2 breakthrough infection between 1-3 or 3-6

months post-third-dose was reclassified into the "HYBRID" group at their following study visit (black

circles). At six months post-third-dose, the black symbols in the HYBRID group denote recent

infections occurring between 3-6 months, while the grey symbols denote participants who had been

infected between 1-3 months. Red bars indicate median and IQR. Comparisons between independent

groups were performed using the Mann-Whitney U-test; longitudinal paired comparisons were

performed using the Wilcoxon matched pairs test. P-values are not corrected for multiple comparisons.

Panel B: Temporal declines in anti-RBD IgG responses following three-dose vaccination in HCW

(blue) and OA (orange) who remained COVID-19-naive during follow-up, and who completed all three

post-third dose visits. *Panel C*: Estimated IgG half-lives following three-dose vaccination, calculated

by fitting an exponential curve to each participant's data in panel B. Red bars and whiskers represent

the median and IQR. P-values were computed using the Mann-Whitney U-test.

Figure 2. Functional humoral responses following three-dose COVID-19 vaccination. *Panel A:*

Same as Figure 1A, but for ACE2 displacement activity, where results are reported in terms of %

ACE2 displacement. *Panel B:* same as Figure 1A, but for virus neutralization activity, defined as the

lowest reciprocal plasma dilution at which neutralization was observed in all wells of a triplicate assay.

Serial two-fold dilutions of 1/20 (lower limit of quantification; LLOQ) to 1/2560 (upper limit of

quantification; ULOQ) were tested. Plasma samples showing neutralization in fewer than three wells at

a 1/20 dilution are displayed as a reciprocal dilution of "10" and were reported as below limit of

quantification (BLOQ) in the text. Note that many datapoints are superimposed.

Supplemental Figures

Figure S1: Longitudinal humoral responses to WT and Omicron variants following three-dose

COVID-19 vaccination. *Panel A:* Longitudinal serum anti-RBD IgG concentrations specific to WT

(left side) and Omicron BA.1 (right side) in health care workers (HCW; blue circles) and older adults

(OA; orange circles). Blue and orange symbols are jittered for visualization. Participants are stratified

into three groups: COVID-19-naive, SARS-CoV-2 infection between 1-3 months post-third-dose, and

SARS-CoV-2 infection between 3-6 months post-third-dose. P-values are computed using the

Wilcoxon matched pairs test and are not corrected for multiple comparisons. Horizontal red lines

denote the overall median response at each time point (where HCW and OA are treated as a combined

group). *Panel B*: Same as A, but for ACE2 % displacement activity in serum. *Panel C*: Same as A, but

for viral neutralization activity in plasma, defined as the lowest reciprocal plasma dilution at which

neutralization was observed in all triplicate assay wells. Serial two-fold dilutions of 1/20 (lower limit of

quantification; LLOQ) to 1/2560 (upper limit of quantification; ULOQ) were tested. Plasma samples

showing neutralization in fewer than three wells at a 1/20 dilution are displayed as a reciprocal dilution

of "10" and were reported as below limit of quantification (BLOQ) in the text. Note that many

datapoints are superimposed.

Figure S2: Omicron-specific anti-RBD IgG decline following three-dose COVID-19 vaccination.

Panel A: Temporal declines in Omicron (BA.1)-specific anti-RBD IgG responses following three-dose vaccination in HCW (blue) and older adults (orange) who remained COVID-19 naive during follow-up, and who completed all three post-third dose visits. *Panel B*: Estimated Omicron (BA.1)-specific IgG half-lives following three COVID-19 vaccine doses, calculated by fitting an exponential curve to each participant's data shown in panel B. Red bars and whiskers represent the median and IQR. P-values were computed using the Mann-Whitney U-test.

Figure S3: Anti-S IgG and ACE2 displacement activities against an expanded panel of Omicron variants. *Panel A:* Concentrations of IgG capable of binding WT, Omicron BA.1, BA.2 and BA.3 Spike proteins in a subset of n=25 participants measured one month post-third vaccine dose. HCW in blue; OA in orange; dots are jittered for visualization. P-values are computed using the Wilcoxon matched pairs test and are uncorrected for multiple comparisons. Horizontal red lines denote the overall median response to each variant (HCW and OA are treated as a combined group). *Panel B*: same as Panel A, but for ACE2% displacement activity. *Panel C*: Correlation between WT and Omicron BA.1-specific anti-Spike IgG concentrations (shown in this figure) with the original anti-RBD IgG measurements shown in the primary analysis (in Figure 1A). *Panel D*: Correlation between WT and Omicron BA.1-specific anti-Spike ACE2 displacement with the original anti-RBD measurements shown in the primary analysis.

REFERENCES

1. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet **2021**; 398:2093-100.

2. Moreira ED, Jr., Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med **2022**; 386:1910-21.

3. Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged >/=60 Years. JAMA **2021**; 326:2203-4.

4. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature **2022**.

5. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med **2022**; 386:1804-16.

6. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med **2022**; 386:1532-46.

7. Christensen PA, Olsen RJ, Long SW, et al. Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. Am J Pathol **2022**; 192:642-52.

8. Staerke NB, Reekie J, Nielsen H, et al. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. Nat Commun **2022**; 13:4466.

9. Mwimanzi F, Lapointe HR, Cheung PK, et al. Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose. J Infect Dis **2022**.

10. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol **2022**; 7:eabn8014.

11. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol **2020**; 38:1073-8.

12. BC Centre for Disease Control. Weekly update on Variants of Concern. Available at: http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data. 2022.

13. Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. J Infect Dis **2022**; 225:1129-40.

326   14. Chen Y, Tong P, Whiteman N, et al. Immune recall improves antibody durability and breadth to
327   SARS-CoV-2 variants. Sci Immunol **2022**:eabp8328.

328   15. Curlin ME, Bates TA, Guzman G, et al. Omicron neutralizing antibody response following booster
329   vaccination compared with breakthrough infection. medRxiv **2022**.
330

Figure 1

Figure 2

Table 1: Participant characteristics

Characteristic	HCW (n=69)	Older Adults (n=47)
Sociodemographic and health variables		
Age in years, median [IQR]	40 [34-51]	78 [72-83]
Female sex at birth, n (%)	53 (77%)	34 (72%)
white Ethnicity, n (%)	32 (46%)	35 (74%)
Number of chronic health conditions, median [IQR]	0 [0-1]	1 [0-2]
Vaccine details		
Initial regimen		
BNT162b2 - BNT162b2	67 (97%)	38 (81%)
mRNA-1273 - mRNA-1273	1 (1.5%)	7 (15%)
heterologous mRNA	1 (1.5%)	2 (4%)
Third dose		
BNT162b2	33 (48%)	18 (38%)
mRNA-1273	36 (52%)	29 (62%)
Date range that third doses were received	Oct 2021-Feb 2022	Oct 2021-Jan 2022
Time between second and third doses in days, median [IQR]	210 [199-232]	198 [173-216]
Specimen collection		
1 month after third dose, n (%)	68 (99%)	47 (100%)
3 months after third dose, n (%)	68 (99%)	45 (96%)
6 months after third dose, n (%)	57 (83%)	44 (94%)
Post-vaccination SARS-CoV-2 infections, n (%)	30 (43%)	8 (17%)